November 13-14, 2019 — Boston, MA
Event: Personalized Medicine Conference
Topic: Prospecting the Pipeline: Exploring the Implications of a Biopharmaceutical Pipeline Dominated by Personalized Treatments
This panel discussion will explore the scientific, regulatory, reimbursement and other systemic issues associated with future gene editing treatments, gene therapies, immunotherapies and targeted therapies. The panelists will also consider a new approach to immunotherapy for cancer patients, in which a unique product is developed for every patient treated.
Meg Tirrell, Reporter, CNBC
- Alex Vadas, Ph.D., Managing Director, Partner, L.E.K. Consulting
- Donald L. Siegel, Ph.D., M.D., Director, Division of Transfusion Medicine & Therapeutic Biology, Director, Clinical Cell and Vaccine Production Facility, University of Pennsylvania’s Perelman School of Medicine
- Harpreet Singh, Ph.D., CEO, Immatics
- Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson
Thursday, November 14, 2019
Harvard Medical School
Time: 10:45-11:45 a.m.
About Alex Vadas
Alexander Vadas is a Managing Director and Partner in L.E.K. Consulting’s Biopharmaceuticals and Life Sciences practice. He joined L.E.K. in 2000 and focuses on diagnostics, research tools and personalized medicine. Within those areas, Alex has worked with a range of established and emerging clients in the areas of corporate strategy, product strategy, and planning and transaction support. He received both his BS and his Doctor of Philosophy in chemical engineering from the University of California, Los Angeles.
Personalized Medicine Conference
The 15th Annual Personalized Medicine Conference will explore the science, business, and policy issues facing personalized medicine as scientists refine their understanding of how groundbreaking molecular diagnostics augmented by artificial intelligence, advanced data analytics, and digital health applications can empower both physicians and patients with information about how an expanded set of biological characteristics may influence their health and their responses to increasingly impactful therapies.
About L.E.K. Consulting
L.E.K. Consulting is a global management consulting firm that uses deep industry expertise and rigorous analysis to help business leaders achieve practical results with real impact. We are uncompromising in our approach to helping clients consistently make better decisions, deliver improved business performance and create greater shareholder returns. The firm advises and supports global companies that are leaders in their industries — including the largest private- and public-sector organizations, private equity firms, and emerging entrepreneurial businesses. Founded in 1983, L.E.K. employs more than 1,400 professionals across the Americas, Asia-Pacific and Europe. For more information, go to www.lek.com.